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ABSTRACT 
Chronic infections are controlled by a variety of mechanisms, including the induction of oxidative stress. Some viral 
infections reduce the ability to defend against pro-oxidant strains, especially in liver cells. Oxidative and nitrosative 
stress can damage cellular membranes, disrupt mitochondrial function, alter gene expression, promote the apoptosis 
and necrosis of hepatocytes, and increase fibrosis in diverse acute andchronic liver diseases. Chronic infections 
caused by the hepatotropic viruses hepatitis B virus and hepatitis C virus are the main risk factors for the 
development of hepatocellular carcinoma. Despite the obvious clinical importance of virus-associated hepatocellular 
carcinoma, the underlying molecular mechanisms are not fully understood. Oxidative stress plays an important role 
in carcinogenesis, especially with DNA lesions caused by oxidative damage additionally there are strongly linked to 
the development of many cancers, including hepatocellular carcinoma.Many studies have shown that both hepatitis 
B virus and hepatitis C virus cause hepatic oxidative stress. 
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INTRODUCTION
Oxidative stress (OS) is triggered when the 
concentration of oxygen species in the extracellular or 
intracellular environment exceeds antioxidant defenses. 
It can also be described as irregular redox signaling and 
control. [1]Normally in all of our body cells have a 
balance in the oxidation/reduction system that is crucial 
to the cells’ survival. If this balance breaks down for 
any reason, either the oxidant levels increase or the 
antioxidant levels decrease, which is termed a state of 
“OS”.It is harmful to the cell. The structure of 
macromolecules in the cell, such as DNA, lipid, protein 
breaks down in the oxidative stress conditions.[2,3]OS 
causes oxidative damage to the structure of 
biomolecules, thereby altering their physiological 
functions. To prevent the harmful effects of reactive 
oxygen species (ROS), biological systems have 
developed a variety of detoxification mechanisms 
using a large number of small molecules, peptides and 
enzymes, like glutathione (GSH) or superoxide 
dismutase (SOD), respectively. 
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OS also triggers the nitrosative stress caused by 
reactive nitrogen species (RNS) and thus results in 
cellular signalling deterioration and cellular damage. 
The results of the studies reported that oxidative and 
nitrosative DNA damage was seen in carcinogenesis 
areas, independent of the etiology of the disease.[4] 
ROS and RNS are produced by mitochondrial electron 
transport or by other enzyme systems containing many 
oxido reductases (such as NADPH oxidase which is 
critical for the bactericidal action of phagocytes) in all 
cells types, including hepatocytes. [5]Researchers have 
reported that oxidative stress may lead to an increase in 
calcium leakage in the endoplasmic reticulum(ER) 
lumen and that the same occurs in ER stress.  Increase 
in calcium concentration in cytosol also increases 
mitochondrial ROS production.[1] Many OS related 
illnesses have been reported by Sies [6]in 1985. Some of 
the most studied diseases are neurodegenerative 
diseases(Alzheimer, Parkinson, and others). [2,7,8] 
cellular aging [9],cardiovascular diseases (hyper 
cholesterolaemia, heart failure, hypertension, 
myocardial infarction, ischemia/reperfusion injury, and 
atherosclerosis), and pathologies involving chronic 
inflammation.[10,11]As a result, OS is now seen as a 
major suspect in the pathogenesis of a wide spectrum 
of disease and cancer. Chronic infections caused by 
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factors such as hepatitis B virus  (HBV) and hepatitis C 
virus (HCV) are the main risk factors for the onset and 
progression of hepatocellular carcinoma (HCC). [12] 
Over the world, up to 80% of HCC can be attributed to 
HBV or HCV infection. The results of the study 
indicate that although the viral proteins themselves 
indicate that they contribute directly to tumor 
formation, the underlying mechanisms remain 
uncertain. [13] There are increasing evidence that the 
viral proteins of HBV and HCV may themselves 
contribute to a state of chronic OS in infected 
hepatocytes. OS has great importance for both 
infectious diseases and non- infectious diseases. 
Studies of redox biology have provided a better 
understanding of oxidative stress. [14] The reactive 
molecules tend to nonspecifically oxidize the basic 
biological macromolecules in its environment and thus 
cause acute cell damage or cause gradual deterioration 
of important cell functions. Thus, O2 is the basis of 
aerobic metabolism and ROS production, a 
consequence of aerobic metabolism, is often associated 
with deleterious effects. In addition, ROS, RNS, and 
reactive sulfur species can promote pathogenesis 
through cell signaling. By modifying or participating in 
different signal paths these reactive species can 
modulate gene expression, cell adhesion, cell 
metabolism, cell cycle and cell death, thus contributing 
to pathogenesis. For example, OS may induce the 
proliferation of hepatic stellate cells, TGF-β and 
collagen synthesis. This likely plays an important role 
in the development of liver fibrosis associated with the 
hepatitis virus infection. Furthermore, OS  in hepatitis 
patients may contribute to the development of hepatic 
steatosis and the progression of fibrosis. The hepatic 
metabolism of biological toxins and medicinal agents is 
associated with impaired hepatocyte biochemistry and 
increased ROS and free radicals. It has been reported 
that redox imbalance and OS, causes subclinical 
anicteric hepatitis (acute, recurrent, or chronic), 
necroinflammatory hepatitis, cirrhosis and carcinoma. 
[15-17] The aim of this review was to clarify the role of 
OSin hepatitis B and C so that its results could 
contribute to a better understanding of these diseases 
and its improved treatment or cure. 
Hepatitis B 
HBV is a DNA hepa DNA virus with a 25- to 180-day 
incubation period. It is estimated that 5% of the world 
population have hepatitis B. Although it has been 50 
years since the discovery of the Australian Antigen by, 
Professor Baruch Samuel Blumberg, the hepatitis B 
virus still affects approximately 350 million individuals 
around the world and is responsible for the deaths of 
about one million people annually. It has been that 
great progress in the prevention, diagnosis, and 
treatment of hepatitis B in the past few decades; 
however, there is not enough evidence to prevent or 
eliminate the disease. In 1983, the production of the 
first hepatitis B vaccine was promising in controlling 
and preventing the disease in the control of the disease. 
In the following years, with the production and 
development of the first antiviral drugs, this point of 
view became even stronger. [18,19]ROS(such as 
superoxide, hydrogen peroxide, singlet oxygen, and 
hydroxyl radicals)and RNS, which are induced by 
various endogenous (e.g., mitochondria, enzymes, etc.) 
and exogenous (e.g., chemicals, tobacco, ultraviolet 
rays, etc.) factors lead to widespread oxidative damage 
to different biomolecules including lipids, proteins, and 
DNA. [2] ROS and RNS are highly unstable and short-
lived species; although these molecules have been great 
cellular signaling, they are particularly difficult to 
direct measure. Therefore, to detect their oxidation 
status, we can measure indirectly, which proteins, 
lipids, and DNA are damaged by the ROS/RNS.  
Lipid peroxidation 
The lipids in cell membranes produce many of the 
reactive products such as malondialdehyde (MDA) 
upon oxidative stress. Many studies have detected that 
the presence of lipid peroxidation in hepatitis B 
infection. [18]MDA has been evaluated as a marker of 
lipid peroxidation product in these studies.MDA 
changes other molecules to produce novel oxidation-
specific epitopes that takes the attention and 
inflammatory reaction of the innate immune system. It 
has been found that MDA is also to attract an immune 
system protein called complement factor H.  This 
factor stops the uptake of MDA-modified proteins by 
macrophages after binding to MDA. This is 
demonstrated by neutralizing the inflammatory effects 
of MDA in the mouse model.[20] It was founded 
significantly higher in patients with hepatitis B 
infection compared to healthy individuals. [21,22] We 
also found MDA values consistent with these outcomes 
in the HBV patient group.[23] Moreover, in our study 
MDA levels were not correlated with biochemical 
parameters, necro-inflammatory activity, fibrosis score 
or viral load in subjects with CVH-B infection. Some 
studies have reported that a correlation between MDA 
levels and alanineaminotransferase (ALT) [21, 22, 24, 25], 
HBV-DNA [21, 26], total and direct bilirubin.[ According 
to these results, lipid peroxidation and its products can 
be said to activate hepatic stellate cells and lead to 
active fibrogenesis. However, Severi et al.  has been 
showed that although of HBV replication produced OS, 
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it did not significantly affect lipid peroxidation product 
levels in their invitro model study.[28] Previous studies 
in this field have generally assessed plasma and 
erythrocyte levels of lipid peroxidation products. In 
future studies, it would be more useful to investigate 
lipid peroxidation product concentrations in the hepatic 
tissue 
Protein Oxidation 
Increased oxidative stress can damage proteins with 
various mechanisms. Nitrotyrosine, Oxidases, protein 
hydroxides and carbonyl derivatives have been studied 
as protein oxidation products. Protein oxidative 
products are more stable and suitable markers than 
lipid oxidation of OS. In addition, protein oxidation 
byproducts can provide valuable clues about the origin 
and severity of oxidative stress.For example, 
nitrotyrosylresidues are produced by HOCl and 
indicate the presence of nitric oxide and superoxide or 
cholortyrosine residues in the presence of neutrophils 
and / or monocytes.  [29, 30]Nitrotyrosine is a product of 
peroxynitrite mediated tyrosine nitration, which is an 
indication of increased peroxynitrite formation and 
nitrosative stress. Our study showed that no significant 
difference between the plasma nitrotyrosine levels of 
healthy individuals and chronic viral hepatitis B 
patients. [23]However, one study performed by Meng et 
al. demonstrated a significant increase in the serum 
nitrotyrosine levels of patients with chronic hepatitis B. 
[31]All of in these studies OS parameters have been 
detected in samples sera or plasma. However, in viral 
liver patients, the plasma or serum levels may not 
reflect accumulation of nitrotyrosine in the hepatic 
tissue.In addition, it has been reported that intrahepatic 
nitrotyrosine accumulation is present in viral liver 
diseases, but not in non-viral diseases, and a 
statistically significant relationship is found between 
the amount of intrahepatic NTY and the severity of 
viral liver disease[32].On the other hand in our study, it 
was detected that plasma NTY levels did not correlate 
with HAI, fibrosis score or viral load.Taşdelen et al has 
been performed that a significant carbonyl level 
increase was identified in chronic active andinactive 
hepatitis B patients compared with the controls. They 
also have been noted a mild to moderate correlation 
between HBV DNA and carbonyl levels, which may 
indicate that several degrees of OS occur in hepatitis B 
infection. [26] In a study performed by Popadiuk et al 
has been detected significantly enhanced plasma 
carbonyl levels in children with chronic hepatitis B 
infection.[33] Additionally increased plasmacarbonyls 
were also identified in patients with HBV-related HCC. 
[34]For this reason, the measurement of protein 
oxidation products is of great value. The increase in the 
level of each product may be a guide in elucidating the 
underlying pathogenesis of the disease. This is why 
protein oxidation needs to be studied further. There is 
no single method for measuring protein oxidation and a 
separate method is applied for each parameter. 
DNA oxidation 
OS can produce a various of DNA damage, which can 
lead to mutations and defects in genome structure. 
Olinski et al has been showed that 8-oxo-7, 8-dihydro-
2’-deoxyguanine (8-oxo-dG) is the most suitable to be 
measured as an oxidative DNA marker.[35] In a study 
done by Shimoda et al.  reported an  increased 
formation of 8-hydroxydeoxyguanosine (8OHdG) in 
chronic hepatitis patients livers. [36] It has been found 
that an increase in the oxidative DNA damage in 
patients with CVHB as the disease progressed from the 
earlier to the later stages and eventually led to HCC.  
Hepatic oxo8dg levels were higher at advanced stages 
than from CVHB patients with no fibrosis.[37] Kitada et 
al. showed that chronic HBV patients had extensive 
DNA damage in liver tissues by 8OHDG immuno-
labeling. [38] Urinary 8OHDG levels were also 
increased in patients with chronic hepatitis. [39]The 
hepatic 8OHdG levels from the tissue samples of 
CVHB indicated extensive DNA oxidation occurring in 
the liver,Additionally this hepatic 8OHdG reactivity 
was strongly correlated with ALT, AST, HBV-DNA 
titers, and age (respectively r = 0.506, 0.515, 0.540 and 
- 0.559) in CVHB patients [40].Although the results of 
these studies indicate the presence of DNA oxidation 
and damage in HBV, there is a need to work more 
focused on DNA oxidation. 
ROS-Producing Enzymes and ROS/RNS 
Production 
ROS/RNS Production 
ROS/RNS species, which originate from oxidative or 
nitrosative stress are highly unstable. So it is difficult 
to measure directly. There are a few study measured 
ROS/RNS species production in patient with HBV in 
the literature. A study by Bhargava et al. reported 
increased ROS levels in lymphocytes of chronic and 
occult  hepatitis B patients. [41]It has been reported that 
increased NO levels in CVHB. But Guler et al.  did not 
find any significant differences compared to healthy 
controls. [42] In addition Tsai et al indicated that there is 
a significant increase in superoxide anion radicals in 
HCC patients associated with HBV.[43]  Nagoev et al 
had been seen that this anions were increased also in 
the leukocytes of patients with CVHB. [44]It is 
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important to disclose correlations between ROS / RNS 
production and hepatitis B disease activity.  
ROS-Producing Enzymes 
Multiple enzymes, including cytochrome P450, 
peroxisomal oxidases, cyclooxygenases, lipo-
oxygenases, and the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidases, are associated with the 
formation of ROS.Such as NADPH oxidase (NOX 
family), myeloperoxidase (MPO) and xanthine oxidase 
enzymes can generate ROS/RNS species.Detection of 
the activities of these enzymes in hepatitis B patients 
will provide a better understanding of the role of 
oxidative and nitrosative stress in this infection. [45]In 
the meantime, it should be noted that the enzymes that 
produce ROS are more important. 
Myeloperoxidase 
Myeloperoxidase (MPO) is a lysosomal heme protein 
that is abundant in granules of human inflammatory 
cells such as activated neutrophils, macrophages and 
monocytes. MPO acts as a master enzyme in the 
generation of a range of ROS by catalyzing the 
conversion of hydrogen peroxide (H2O2) to species 
including •OH, ONOO−, hypochlorous acid (HOCl), 
and NO2. MPO-derived ROS can then modify lipids, 
lipoproteins and proteins.MPO enzyme activity is 
readily measurable, so it is  one of the promising 
biomarkers of OS. [45]We have been seen that 
significantly decreased plasma MPO levels were in 
patients with hepatitis B when compared to healthy 
controls. However, this difference was not correlated 
with viral load, necroinflammatory activity or fibrosis 
score in the liver.[23] A study by Tasdelen et al. revealed 
a significant decrease in the mean plasma MPO levels 
in HBV patients compatible with our result and this 
decrease was shown to have a significant negative 
correlation with the HBV DNA levels in both active 
and inactive hepatitis B patients. [26] The plasma of 
hepatitis B patients was used in these studies and MPO 
levels in hepatic tissue samples were not 
measured.Considering the excessive amount of 
oxidation in patients with hepatitis B, presumably very 
high levels of plasma MPO may be expected. 
Therefore, this unexpected result could probably be 
attributed to the site of sampling or cause the severity 
and progression of the viral disease. But there are also 
conflicting results in the literature.  A group of 
investigators found a significant increase in plasma 
MPO activities in HBV-associated cirrhotic patients 
and found no significant difference between healthy 
controls and CHBV patients. There was also a positive 
correlation between plasma MPO activity and liver 
fibrosis..These results suggest that MPO plasma levels 
may be indicative of disease progression. Thus, plasma 
enzyme activity levels of patients may not increase 
significantly until cirrhosis occurs. Guler et al.  
detected that a significant increase in serum MPO 
activities was observed in chronic active and inactive 
hepatitis B compared to healthy controls. Enzyme 
activities have been also positively correlated with the 
patients’ DNA and ALT levels. [42]As a result, further 
extensive studies are needed to clarify the exact state of 
the MPO in hepatitis B. 
Hepatitis B and Antioxidants 
Le Châtelier principle, one of the most important laws 
of chemistry, emphasizes that a system in balance will 
remain in balance as long as it is not disturbed. In 
normal physiological conditions, the human body 
provides its own balance by using oxidants and 
antioxidants. OS occurs when this balance is impaired 
by some environmental factors. OS is a disorder that 
leads to a potential cellular damage. Most cells can 
tolerate a mild degree of OS, because they have 
sufficient antioxidant defense capacity and repair 
systems, which recognize and remove molecules 
damaged by oxidation. It is known that OS is 
associated with more than over 100 diseases. [47] Our 
antioxidant defense system consists of two synergistic 
compartments: endogenous antioxidants (e.g., 
superoxide dismutase, glutathione peroxidase, catalase, 
glutathione etc.)  and exogenous antioxidants. It is 
reported that our immune system should be 
supplemented with exogenous antioxidants such as 
vitamin C, vitamin E and carotenoids.[48] Detection of 
antioxidant status in hepatitis B and a better 
understanding of antioxidant supplementation therapy 
will guide the progression of the disease. There are 
many studies showing antioxidant status in CVHB 
patients. We showed that erythrocyte SOD, catalase, 
glutathione peroxidase activities, GSH and serum total 
antioxidant response levels were significantly lower in 
patients than in controls. Additionally, no significant 
correlation was found between these markers and viral 
load, necro-inflammation, and fibrosis of the liver in 
patients with chronic viral hepatitis. [49] GSH is 
synthesized in all types of eukaryotic cells and 
especially found in liver. It is considered as one of the 
most important anti-oxidants. There are a few studies 
in the literature that found reduced levels of GSH in 
erythrocytes of CVHB patients. [25, 26, 50, 51] Tasdelen et 
al has been also found that a negative correlation 
between HBV DNA and erythrocyte GSH levels 
[26]Moreover Kundu et al noted a significant negative 
correlation ALT, AST, GGT, and ALP with 
erythrocytes glutathione levels in CVHB patients.[25] 
Some researchers have reported increase levels of 
plasma GSH in acute hepatitis B patients.[51]  Because 
of this unexpected increase, there may be 
compensatory mechanisms seen at the beginning of a 
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disease.  It has been reported that despite the initial 
increase in plasma glutathione levels in acute hepatitis 
B patients, it began to fall as the disease became more 
severe and chronic. Also in patients with chronic 
hepatitis B and severe acute hepatitis B, erythrocyte 
GSH were decrease with plasma glutathione levels 
decrease simultaneously.[51] We and some researchers 
have been reported decreased levels of glutathione 
peroxidase [26, 49, 52] while there was an increase in 
another study. It has been reported that low SOD and 
catalase activity and elevated lipid peroxidation levels 
in chronic B hepatitis patients indicate deficient 
antioxidant defense.[53] The erythrocyte SOD activities 
of hepatitis B patients were lower than controls, and 
the results of these studies were compatible. [26, 33, 49] 
But there are conflicting results regarding serum SOD 
activities. [31, 43, 54, 55] Catalase, which is an important 
antioxidant enzyme, has been measured in both 
erythrocyte and serum levels. The results are not 
compatible.[26, 49, 53, 56]The total antioxidant capacity 
parameter which with worked different methods (TAS, 
TAC) was found to been decreased in all hepatitis B 
patient groups. [21, 49, 57-59]There was detected a decrease 
in the products of lipid peroxidation (as MDA levels) 
and an increase in the antioxidant enzymes, such as 
CuZnSOD and GSH-Px in HBV patients after 
treatment with interferon-α and lamivudine, compared 
with pretreatment.[22] There may be factors causes of 
contradictory outcomes include methodology, sample 
size, statistical analysis, disease progression, control 
group difference, etc. However, these controversial 
outcomes are indicative of a complex OS process. 
More extensive studies will be needed to determine the 
role of different antioxidants in hepatitis B. 
Hepatitis C 
The HCV infection is a major biomedical problem, 
with an incubation period of 11–150 days is 
transmitted primarily via infected blood more than 150 
million humans infected worldwide, which accounts 
for approximately 3–4 million new cases of viral 
hepatitis each year. Differently from the other hepatitis 
viruses (A, B, and E), more than 80% of HCV patients 
become chronic.It is known that chronic HCV infection 
is associated with liver inflammation (hepatitis), 
fibrosis, cirrhosis and hepatocellular carcinoma. 
[60]Hence, HCV infection is the leading cause of liver 
transplantation worldwide. There is no effective 
vaccine against HCV and current treatments are only 
partially effective.  Proper diagnosis of infected 
patients is essential for the effectiveness of the 
treatment. [61]This was reported that HCV produces 
more ROS than other hepatitis viruses and patients 
with chronic hepatitis C have over 80% chances of 
developing chronic diseases as compared to patients of 
hepatitis A, B and E. [62] Hepatic OS, a prominent 
feature of chronic hepatitis C infection, is seen in a 
number of inflammatory liver diseases. [40] HCV 
infection is known to cause activation of the immune 
system and macrophages, and therefore ROS can be 
produced by blood cells. Cell damage  caused by OS is 
known to play an important role in the pathophysiology 
of HCV. There are also studies showing that chronic 
HCV infection is caused by mitochondrial dysfunction 
and OS.[63]OS can also occur when HCV components 
are taken up by the liver kupffer cells. Active kupffer 
cells have been reported to contribute to the killing of 
hepatocytes by various mechanisms. These cells 
enhance not only the local production of cytokines 
such as TNF-α but also ROS production. [64] However, 
the mechanisms by which Kupffer cells cause OS and 
liver damage are not fully understood. Damaged 
hepatocytes release ROS in the extracellular 
environment, leading to the activation of hepatic 
stellate cells.It is well known that the largest part of the 
ROS produced in the cells is derived from 
mitochondria. Mitochondria, which are the power 
plants of the cells, are the main targets of HCV virus. It 
was also detected that HCV produces ultrastructural 
changes in these organelles and causes oxidative 
damage and a reduction in mitochondrial DNA copy 
number, in both hepatocytes and lymphocytes of 
infected patients. [65] In HCV, increases in NADPH 
oxidase have been reported to increase ROS and RNS, 
which may lead to chronic inflammation in these 
patients. [15] Although HCV core and other proteins 
primarily localizes to the ER, it also associates with 
mitochondria. Oxidative DNA damage increases 
chromosomal aberrations associated with cell 
transformation, and OS plays a role in the development 
of HCC associated with HCV. For example, increased 
ROS / RNS levels have been found to promote DNA 
damage and hepatocellular carcinoma development by 
increasing mutations in cellular genes. [66] In animal 
modeling and culture systems studies, it has been 
observed that HCV- expressed proteins directly destroy 
the mitochondrial respiratory chain with 
overproduction of ROS. Thus the structure and 
function of mitochondria may change in infected 
hepatocytes. Thus, it is suggested that the 
mitochondria’s structure and function may change of 
infected hepatocytes. [62]The transcriptional and 
replication mechanisms of mitochondria are 
upregulated so that mitochondrial  biogenesis increases 
with mitochondrial genome replication in OS 
conditions. In these damaged mitochondria can be 
inhibited by the electron transport chain, which can 
lead to ROS accumulation.[67] Three mechanisms are 
known to contribute to HCV-associated OS; These 
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include (i) mitochondrial dysfunction; (ii) ER stress 
and (iii) immune cell-mediated oxidative bursts.The 
HCV core protein is known to be strong in this respect 
and and its expression is sufficient to produce OS. [68]It 
is reported that HCV replication induces OS. Oxidative 
stress is thought to be a clinical feature associated with 
hepatitis C infection, little is known about how the 
virus can survive in a highly oxidative environment. 
OS adaptation is predicted to be the key to the survival 
of the virus.[69] There are some studies that use 
antioxidants in clinical trials in the treatment of HCV 
patients. [70-72]Many different OS markers have been 
studied in hepatitis C patients, including lipid 
peroxidation products and oxidized protein and 
ROS/RNS producing enzymes.[23,73,74] 
Some investigators have found that high levels of OS 
markers correlate with the severity of the disease in 
hepatitis C patients and that OS decreases after 
successful treatment. [73, 75] 
Lipid peroxidation 
MDA release and hepatic damage by membrane lipid 
peroxidation were found to be induced by GSH 
depletion in HCV patients. De Maria et al have shown 
that (i) lipid oxidation occurs in chronic hepatitis C, (ii) 
oxidative damage has increased levels of MDA, and 
(iii) MDA levels correlate with disease activity.These 
results arein accordance with the findings of other 
investigators and our result. [23, 76] We detected also that 
plasma MDA levels were significantly higher in the 
CVH-C patients than the controls ( p < 0.001). 
Additionally in patients with CVH-C, Spearman’s 
correlationanalysis showed no significant correlation 
betweenplasma MDA,  viral load ( HCV-RNA), 
fibrosis score and HAI (p > 0.05).Increased lipid 
peroxides may be chemotactic effect for neutrophils 
leading to increased inflammation, resulting in oxidant-
mediated injury in the liver. 
Protein and DNA Oxidation 
Lipid peroxidation/ advanced oxidation protein 
products and 8-hydroxy deoxyguanosine (8-OHdG) are 
biological molecules modified with ROS.  These 
molecules were found at significantly higher levels in 
PBMCs in HCV patients compared to healthy controls.  
[76- 79]In CHC patient liver samples were detected a 
significant increase of 8-OHdG levels. [38] Recently, 
several mechanisms have been proposed that may 
contribute to the replacement of cell fate by forming 
ROS-induced apoptosis tumor occurrence in the 
animals. First, OS leads to DNA damage (including 8-
OHdG) and accumulation of mutations.Liu et al 
reported that nitration of tyrosine, in both protein-
bound form and free amino acid form, can readily 
occur in cells under oxidative/nitrative stress. [80] 
Nitrotyrosine 
Viral hepatitis has been found to be associated with an 
increased iNOS expression, and there is also a 
suspicious relationship with iNOS expression and 
disease severity. Increased iNOS expression increases 
the amount of RNS, which is associated with DNA 
damage, and NO plays a role in the development of 
HCC as DNA damage causes cancer development. 
García-Monzón et al demonstrated that the intrahepatic 
accumulation of NTY - a marker of  peroxynitrite 
attack on cellular proteins - was positively related to 
the severity of liver damage in CVH. [32]Recently a 
direct correlation has been documented between iNOS 
induction and hepatitis C virus ribonucleic acid (HCV-
RNA) titer and also hepatocyte nitrotyrosine, plasma 
nitrosothiols and histological severity of liver damage. 
Therefore, in addition to OS, it is thought that 
nitrosative stress may play a role in the pathogenesis of 
chronic viral hepatitis.[80] In our study there were no 
statistically significant differences between the serum 
NTY levels of the patients with chronic HCV and the 
controls (p > 0.05). In addition correlation analysis 
showed no significant correlation between plasma 
NTY with viral load (HCV-RNA), fibrosis score and 
HAI (p > 0.05). 
ROS-Producing Enzymes and ROS/RNS 
Production 
The NADPH oxidase enzyme family is an additional 
source of ROS in HCV-infected cells. This enzyme 
group consists of seven transmembrane enzymes that 
participate in electron transport from the membranes 
and thus produce superoxide anion or H2O2.[81]Studies 
in CHC patients have shown that levels of some 
defense enzymes such as heme oxygenase (HO-1) [82] 
and thioredoxin (Trx) [83]are increased. It has also been 
found that HCV-mediated infections are also a threat to 
the body's antioxidant systems. On the other hand, 
researchers detected decreased levels of manyother 
antioxidant defense enzymes, such as manganeseor 
Cu/Zn superoxide dismutase (SOD), glutathione 
reductase, and glutathione peroxidase, in the 
peripheralblood of the patients of CHC [76, 84] although 
an increase was also reported. [85] 
Myeloperoxidase 
MpO is a multifunctionalenzyme involved in both host 
defense and tissuedamage at inflammatory sites. It 
produces notonly oxidative equivalents, but contributes 
also tothe regulation in general response to invading 
microorganisms. [45] It has been known that HCV 
infection is to causes autophagy,  and OSand alter Ca+2 
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signaling. For this reason, it is thought that it changes 
mt structure and functions.[86] Overall, there is evidence 
that several HCV proteins directly interact with 
mitochondria in hepatocytes and alter their function in 
metabolism, redox balance, ROS scavenging and 
apoptosis.Nevertheless, the underlying molecular 
mechanisms of physical interactions reflect how these 
interactions translate into changing mt functions and 
the role of altered mt functions in the viral life cycle 
and the pathogenesis associated with chronic hepatitis 
C are still not fully understood.In our study plasma 
MPO levels were significantly lower in the CHC 
patients than the controls (p < 0.001). However 
Spearman’s correlationanalysis showed no significant 
correlation betweenplasma MPO with viral load (HBV-
DNAand HCV-RNA), fibrosis score and HAI ın 
patient group (p>0.05).[23] Bekhett et al. reported that 
tissue MPO activity increases significantly in patients 
with CVH-C than the controls, whereas plasma MPO 
activity does not. [87] Do Carmo et al has found that 
patients infected by HCV with HCC had higher MPO 
plasma levels than patients without HCC. MPO levels 
in patients with HCC have been found approximately 
three fold more often than patients with chronic HCV 
or severe fibrosisThese study results support the idea 
that MPO might have a role in the HCC development 
[88] 
HCV and Antioxidants 
It is known that ROS / RNS plays a role in the onset 
and progression of the disease and its malignant 
transformation in patients with hepatitis C.However, 
the results of studies in which antioxidants are used in 
therapy of animals and of patients with HCV are 
contradictory.Researchers have reported that 
antioxidants may be employed in 4 different ways 1) to 
impair in HCV replication 2) to improveliver enzyme 
levels, 3) to protect against liver cell damageand 4) to 
render interferon anti-viral therapy more 
effective.HCV induces OS via several molecular 
pathways, for example mitochondrial damage and 
altered metal homeostasis; It is difficult to think of an 
antioxidant approach with such a wide spectrum of 
action. Antioxidants such as N-acetylcysteine (NAC), 
vitamin E, or ascorbic acid, when used alone, have 
been shown to improve liver damage in patients with 
HCV but not affect HCV titres. [88] It has been shown 
to exhibit reduced levels of GSH and other antioxidants 
as well as reduced total antioxidant activity in blood 
and liver biopsies in a large proportion of CHC 
patients. [89-91,77]We have been detected decreased 
levels of GSH and TAS in blood of CHC 
patients[49].Decreased GSH may be a consequence of 
liver damage.Studies have shown that GSH levels in 
liver and circulation of patients with chronic HCV 
cirrhosis are reduced. [80]Proteomic analyzes revealed 
an upregulation of antioxidant enzymes in the early 
phase (F1 to F3), but not in the late stages of fibrosis. 
[92] It has been reported that low catalase and SOD 
activity and elevated lipid peroxidation levels in 
chronic C hepatitis patients indicate deficient 
antioxidant defense.[53] It has been also displayed 
decreased levels of antioxidant defense enzymes such 
as SOD, glutathione reductase, catalase and glutathione 
peroxidase were also often found in blood of CHC 
patient. [49, 76, 84] Larrea et al has found that expression 
of the same enzymes was not altered in liver of the 
same patients. [93] Due to the role of OS in HCV 
pathogenesis, antioxidants have been proposed to treat 
HCV patients. For example, in a clinical trial, 
normalization of liver enzymes was observed in 44% 
of chronic HCV patients with elevated pretreatment 
levels, using a combination antioxidant therapy. In 
addition histological improvement was also noted in 
36.1% of the patients. [72]However, it is not known 
exactly how the increased ROS / RNS affects HCV 
replication. New in vitro cell culture studies supporting 
the entire life cycle of HCV are thought to help clarify 
the complex relationship between OS, HCV, and 
pathogenesis. In another study decrease in viral load 
with improvement in liver enzymes and histology was 
detected in patients receiving oral and intravenous 
combined antioxidant treatment.[92] Although the 
results of these studies demonstrate the beneficial 
effects of antioxidants further studies are needed to 
properly elucidate the types, amounts, and routes of 
antioxidant drug administration that are most 
appropriate. We believe that this antiviral therapeutic 
strategy should not be overlooked, despite the low 
efficacy achieved using antioxidant therapies. 
Continued research is also needed in the areas of 
antioxidant therapy, to assess the effect of OS on the 
disease and thus the potential of antioxidant treatment 
in the attenuation of disease progression. 
DISCUSSION 
A various ROS species are produced as a product of 
cellular metabolism and play an important role in cell 
signaling and regulation of cytokine, growth factor and 
hormoneaction, transcription, ion transport, neuro-
modulation, immune modulation and apoptosis [94] In 
particular, it is known that it plays a fundamental role 
in the normal functioning of the immune system and in 
the proliferation of T cells and in immunological 
defense. [95]There is no doubt that OSplays an 
importantrole in HBV pathogenesis, therefore, the 
combination of various mechanisms can produce new 
solutions to combating the OS in HBV infection. 
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Although the presence of OS in chronic hepatitis C and 
the ability of multiple viral proteins and replicons to 
produce ROS have been clearly establishedthe 
contribution of OS to pathogenesis is still 
unclear.Activated Kupffer cells stimulate hepatic 
stellate cells to release cytokines and chemokines and 
promote liver fibrogenesis. Kupffer cells also release 
reactive oxygen species, nitric oxide and chemotactic 
proteins, which stimulate hepatocyte damage and 
increase inflammatory response.[96] NADPH oxidase 
enzyme can stimulate the production of ROS in hepatic 
stellate cells, macrophages and hepatocytes. This OS 
on the hepatocytes can damage deoxyribonucleic acid 
(DNA), induceapoptosis, promote the expression of 
pro-inflammatorygenes, enhance fibrogenesis, and 
possibly trigger malignant transformation.[97] Inducible 
nitric oxide synthase (iNOS) may increase hepatocyte 
toxicity by increasing nitric oxide production, and the 
nuclear factor kappa-light chain enhancer of activated 
B cells (NF-kB) can regulate iNOS production and OS. 
[98]As a net result of these various interactive cellular 
and molecular mechanisms, tissue damage continues 
and increases the accumulation of extracellular matrix 
collagen.[99]Conventional treatment strategies should be 
modified to focus on the prevention of hepatic fibrosis 
and these changes should provide rapid viral clearance 
and quick complete suppression in the liver 
inflammation. [99] Even if the cell cytoplasm appears 
healthy, the cells may be under OS, so conventional 
methods used to determine OSmust be re-evaluated. 
Most importantly, solutions must be permanent. 
CONCLUSION 
The role of OSin chronic hepatitis triggered liver 
damage is an important area of research, particularly 
because that information could be of major therapeutic 
value in protecting the liver.In the form of ROS and 
RNS, this OScan damage all of the cells present in the 
liver, including hepatocytes, Kupffer cells, stellate 
cells, and endothelial cells, by induction of 
inflammation, ischemia, fibrosis, necrosis, apoptosis, 
or malignant transformation through damage to lipids, 
proteins, and/or DNA.Despite the common OS in 
hepatitis B, antioxidant therapy is not always 
considered a treatment strategy, because if antioxidants 
are not used at the right time and in the right 
combination they can act like prooxidants. For this 
reason, large-scale studies will be needed to determine 
appropriate antioxidant treatments. Natural compounds 
are known to be potent antioxidants, and some are able 
to bind Cu and Fe and thus control redox potentials. It 
is known that OSplays an important role in the 
pathogenesis of HCV, therefore the combination of 
various mechanisms described in studies can be used to 
obtain new solutions of OSin HCV infection.OS 
biomarkers (lipid peroxidation, DNA damage, some 
protein isolation / expression) help to define a 
physiological state over time. Measurement of 
biomarkers allows for the elucidation of the presence 
of oxidative stress, but does not indicate the cause of 
this stress. The presence of OS may suggest causality, 
but using biomarkers alone may lead to only a 
correlation, not causality.A few of the studies 
mentioned in this review indicated that there is a 
correlation between OS markers and liver pathology. 
Causality can be deduced from these results, but not as 
proven.As the basic information about the role of OS in 
the development of the disease and the underlying 
mechanisms of ROS-related cell toxicity continues to 
emerge these findings will provide guidance for more 
rational antioxidant therapeutic approaches. 
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